The development of fluorescence guided surgery for pancreatic cancer: from bench to clinic

References

• Rosenthal EL, Warram JM, de Boer E, et al. Successful translation of fluorescence navigation during oncologic surgery: a consensus report. J Nucl Med Off Publ Soc Nucl Med. 2016;57:144–150.
   PubMed Web of Science ®Google Scholar
• Verbeke CS. Resection margins and R1 rates in pancreatic cancer – are we there yet? Histopathology. 2008;52:787–796.
   PubMed Web of Science ®Google Scholar
• Verbeke CS, Menon KV. Redefining resection margin status in pancreatic cancer. HPB. 2009;11:282–289.
   PubMed Web of Science ®Google Scholar
• Esposito I, Kleeff J, Bergmann F, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008;15:1651–1660.
   PubMed Web of Science ®Google Scholar
• Moss RA, Lee C. Current and emerging therapies for the treatment of pancreatic cancer. OncoTargets Ther. 2010;3:111–127.
   PubMed Web of Science ®Google Scholar
• Rau BM, Moritz K, Schuschan S, et al. R1 resection in pancreatic cancer has significant impact on long-term outcome in standardized pathology modified for routine use. Surgery. 2012;152:S103–S111.
   PubMed Web of Science ®Google Scholar
• Ethun CG, Kooby DA. The importance of surgical margins in pancreatic cancer. J Surg Oncol. 2016;113:283–288.
   PubMed Web of Science ®Google Scholar
• Delpero JR, Jeune F, Bachellier P, et al. Prognostic value of resection margin involvement after pancreaticoduodenectomy for ductal adenocarcinoma: updates from a french prospective multicenter study. Ann Surg. 2017;266:787–796.
   PubMed Web of Science ®Google Scholar
• Ghaneh P, Kleeff J, Halloran CM, et al. The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Ann Surg. 2017.
   PubMedGoogle Scholar
• de Geus SWL, Kasumova GG, Sachs TE, et al. Neoadjuvant therapy affects margins and margins affect all: perioperative and survival outcomes in resected pancreatic adenocarcinoma. HPB. 2018.
   Google Scholar
• De Rosa A, Cameron IC, Gomez D. Indications for staging laparoscopy in pancreatic cancer. HPB. 2016;18:13–20.
   PubMed Web of Science ®Google Scholar
• Mayo SC, Austin DF, Sheppard BC, et al. Evolving preoperative evaluation of patients with pancreatic cancer: does laparoscopy have a role in the current era? J Am Coll Surg. 2009;208:87–95.
   PubMed Web of Science ®Google Scholar
• Allen VB, Gurusamy KS, Takwoingi Y, et al. Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. Cochrane Database Syst Rev. 2016;7:CD009323.
   PubMedGoogle Scholar
• Wang C, Wang Z, Zhao T, et al. Optical molecular imaging for tumor detection and image-guided surgery. Biomaterials. 2018;157:62–75.
   PubMed Web of Science ®Google Scholar
• Wu AM. Engineered antibodies for molecular imaging of cancer. Methods. 2014;65:139–147.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Choyke PL. Target-cancer-cell-specific activatable fluorescence imaging probes: rational design and in vivo applications. Acc Chem Res. 2011;44:83–90.
   PubMed Web of Science ®Google Scholar
• Nagaya T, Sato K, Harada T, et al. Near infrared photoimmunotherapy targeting EGFR positive triple negative breast cancer: optimizing the conjugate-light regimen. PloS One. 2015;10:e0136829.
   PubMed Web of Science ®Google Scholar
• Hussain T, Nguyen QT. Molecular imaging for cancer diagnosis and surgery. Adv Drug Deliv Rev. 2014;66:90–100.
   PubMed Web of Science ®Google Scholar
• Mochida A, Ogata F, Nagaya T, et al. Activatable fluorescent probes in fluorescence-guided surgery: practical considerations. Bioorg Med Chem. 2018 Feb 15;26(4):925-930.
   Web of Science ®Google Scholar
• Tung C-H, Bredow S, Mahmood U, et al. Preparation of a cathepsin D sensitive near-infrared fluorescence probe for imaging. Bioconjug Chem. 1999;10:892–896.
   PubMed Web of Science ®Google Scholar
• Bremer C, Bredow S, Mahmood U, et al. Optical imaging of matrix metalloproteinase–2 activity in tumors: feasibility study in a mouse model. Radiology. 2001;221:523–529.
   PubMed Web of Science ®Google Scholar
• Olson ES, Aguilera TA, Jiang T, et al. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol Quant Biosci Nano Macro. 2009;1:382–393.
   Google Scholar
• Sharma A, Kim E-J, Shi H, et al. Development of a theranostic prodrug for colon cancer therapy by combining ligand-targeted delivery and enzyme-stimulated activation. Biomaterials. 2018;155:145–151.
   PubMed Web of Science ®Google Scholar
• Urano Y, Sakabe M, Kosaka N, et al. Rapid cancer detection by topically spraying a γ-glutamyltranspeptidase–activated fluorescent probe. Sci Transl Med. 2011;3:110ra119110ra119.
   Web of Science ®Google Scholar
• Hanigan MH, Frierson HF, Swanson PE, et al. Altered expression of gamma-glutamyl transpeptidase in human tumors. Hum Pathol. 1999;30:300–305.
   PubMed Web of Science ®Google Scholar
• Miyata Y, Ishizawa T, Kamiya M, et al. Intraoperative imaging of hepatic cancers using γ-glutamyltranspeptidase-specific fluorophore enabling real-time identification and estimation of recurrence. Sci Rep. 2017;7:3542.
   PubMed Web of Science ®Google Scholar
• Kawakubo K, Ohnishi S, Hatanaka Y, et al. Feasibility of using an enzymatically activatable fluorescence probe for the rapid evaluation of pancreatic tissue obtained using endoscopic ultrasound-guided fine needle aspiration: a pilot study. Mol Imaging Biol MIB Off Publ Acad Mol Imaging. 2016;18:463–471.
   PubMed Web of Science ®Google Scholar
• Mori K, Ishizawa T, Yamashita S, et al. Intraoperative visualization of pancreatic juice leaking from the pancreatic stump in a swine model. Gastroenterology. 2015;149:1334–1336.
   PubMed Web of Science ®Google Scholar
• Giannopoulos G, Pavlakis K, Parasi A, et al. The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters. Anticancer Res. 2008;28:1875–1881.
   PubMed Web of Science ®Google Scholar
• Bloomston M, Zervos EE, Rosemurgy AS. Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol. 2002;9:668–674.
   PubMed Web of Science ®Google Scholar
• Metildi CA, Felsen CN, Savariar EN, et al. Ratiometric activatable cell-penetrating peptides label pancreatic cancer, enabling fluorescence-guided surgery, which reduces metastases and recurrence in orthotopic mouse models. Ann Surg Oncol. 2015;22:2082–2087.
   PubMed Web of Science ®Google Scholar
• Unkart JT, Chen SL, Wapnir IL, et al. Intraoperative tumor detection using a ratiometric activatable fluorescent peptide: a first-in-human phase 1 study. Ann Surg Oncol. 2017 Oct;24(11):3167–3173.
   Web of Science ®Google Scholar
• van Dam GM, Themelis G, Crane LMA, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med. 2011;17:1315–1319.
   PubMed Web of Science ®Google Scholar
• Tummers QRJG, Hoogstins CES, Gaarenstroom KN, et al. Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17. Oncotarget. 2016;7:32144–32155.
   PubMedGoogle Scholar
• Assaraf YG, Leamon CP, Reddy JA. The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist Updat. 2014;17:89–95.
   PubMed Web of Science ®Google Scholar
• Parker N, Turk MJ, Westrick E, et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem. 2005;338:284–293.
   PubMed Web of Science ®Google Scholar
• Hosotani R, Kawaguchi M, Masui T, et al. Expression of integrin alphaVbeta3 in pancreatic carcinoma: relation to MMP-2 activation and lymph node metastasis. Pancreas. 2002;25:e30–35.
   PubMedGoogle Scholar
• Liu L, Lin G, Yin F, et al. Near-infrared fluorescent peptide probes for imaging of tumor in vivo and their biotoxicity evaluation. J Biomed Mater Res A. 2016;104:910–916.
   PubMed Web of Science ®Google Scholar
• Handgraaf HJM, Boonstra MC, Prevoo HAJM, et al. Real-time near-infrared fluorescence imaging using cRGD-ZW800-1 for intraoperative visualization of multiple cancer types. Oncotarget. 2017;8:21054–21066.
   PubMedGoogle Scholar
• Boonstra MC, Tolner B, Schaafsma BE, et al. Preclinical evaluation of a novel CEA-targeting near-infrared fluorescent tracer delineating colorectal and pancreatic tumors. Int J Cancer. 2015;137:1910–1920.
   PubMed Web of Science ®Google Scholar
• Sharma R, Kallur KG, Ryu JS, et al. Multicenter reproducibility of 18F-fluciclatide PET imaging in subjects with solid tumors. J Nucl Med Off Publ Soc Nucl Med. 2015;56:1855–1861.
   PubMed Web of Science ®Google Scholar
• Kimura RH, Teed R, Hackel BJ, et al. Pharmacokinetically stabilized cystine knot peptides that bind alpha-v-beta-6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18:839–849.
   PubMed Web of Science ®Google Scholar
• Tummers WS, Kimura RH, Abou-Elkacem L, et al. Development and preclinical validation of a cysteine knottin peptide targeting integrin αvβ6 for near-infrared fluorescent-guided surgery in pancreatic cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2018;24:1667–1676.
   PubMed Web of Science ®Google Scholar
• Cantero D, Friess H, Deflorin J, et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer. 1997;75:388–395.
   PubMed Web of Science ®Google Scholar
• Lee GY, Qian WP, Wang L, et al. Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano. 2013;7:2078–2089.
   PubMed Web of Science ®Google Scholar
• Tummers WS, Farina-Sarasqueta A, Boonstra MC, et al. Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma. Oncotarget. 2017;8:56816–56828.
   PubMedGoogle Scholar
• Pèlegrin A, Folli S, Buchegger F, et al. Antibody-fluorescein conjugates for photoimmunodiagnosis of human colon carcinoma in nude mice. Cancer. 1991;67:2529–2537.
   PubMed Web of Science ®Google Scholar
• Shively JE, Beatty JD. CEA-related antigens: molecular biology and clinical significance. Crit Rev Oncol Hematol. 1985;2:355–399.
   PubMed Web of Science ®Google Scholar
• Folli S, Wagnières G, Pèlegrin A, et al. Immunophotodiagnosis of colon carcinomas in patients injected with fluoresceinated chimeric antibodies against carcinoembryonic antigen. Proc Natl Acad Sci USA. 1992;89:7973–7977.
   PubMed Web of Science ®Google Scholar
• Duraker N, Hot S, Polat Y, et al. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol. 2007;95:142–147.
   PubMed Web of Science ®Google Scholar
• Meng Q, Shi S, Liang C, et al. Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis. OncoTargets Ther. 2017;10:4591–4598.
   PubMed Web of Science ®Google Scholar
• Benini L, Cavallini G, Zordan D, et al. A clinical evaluation of monoclonal (CA19-9, CA50, CA12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer. Pancreas. 1988;3:61–66.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Enjoji M, Tsuneyoshi M. Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9. J Surg Oncol. 1991;47:148–154.
   PubMedGoogle Scholar
• Girgis MD, Olafsen T, Kenanova V, et al. Targeting CEA in pancreas cancer xenografts with a mutated scFv-Fc antibody fragment. EJNMMI Res. 2011;1:24.
   PubMed Web of Science ®Google Scholar
• de Geus SWL, Boogerd LSF, Swijnenburg R-J, et al. Selecting tumor-specific molecular targets in pancreatic adenocarcinoma: paving the way for image-guided pancreatic surgery. Mol Imaging Biol MIB Off Publ Acad Mol Imaging. 2016;18:807–819.
   PubMed Web of Science ®Google Scholar
• Kaushal S, McElroy MK, Talamini MA, et al. Fluorophore-conjugated anti-CEA antibody for the intraoperative imaging of pancreatic and colorectal cancer. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2008;12:1938–1950.
   Google Scholar
• Metildi CA, Kaushal S, Lee C, et al. An LED light source and novel fluorophore combinations improve fluorescence laparoscopic detection of metastatic pancreatic cancer in orthotopic mouse models. J Am Coll Surg. 2012;214:9971007.e2.
   PubMed Web of Science ®Google Scholar
• Metildi CA, Kaushal S, Pu M, et al. Fluorescence-guided surgery with a fluorophore-conjugated antibody to carcinoembryonic antigen (CEA), that highlights the tumor, improves surgical resection and increases survival in orthotopic mouse models of human pancreatic cancer. Ann Surg Oncol. 2014;21:1405–1411.
   PubMed Web of Science ®Google Scholar
• Hiroshima Y, Maawy A, Zhang Y, et al. Fluorescence-guided surgery, but not bright-light surgery, prevents local recurrence in a pancreatic cancer patient derived orthotopic xenograft (PDOX) model resistant to neoadjuvant chemotherapy (NAC). Pancreatol Off J Int Assoc Pancreatol IAP Al. 2015;15:295–301.
   PubMed Web of Science ®Google Scholar
• Maawy AA, Hiroshima Y, Kaushal S, et al. Comparison of a chimeric anti-carcinoembryonic antigen antibody conjugated with visible or near-infrared fluorescent dyes for imaging pancreatic cancer in orthotopic nude mouse models. J Biomed Opt. 2013;18:126016.
   PubMed Web of Science ®Google Scholar
• Lwin TM, Murakami T, Miyake K, et al. Tumor-specific labeling of pancreatic cancer using a humanized anti-CEA antibody conjugated to a near-infrared fluorophore. Ann Surg Oncol. 2018 April;25(4):1079–1085
   Web of Science ®Google Scholar
• Gutowski M, Framery B, Boonstra MC, et al. SGM-101: an innovative near-infrared dye-antibody conjugate that targets CEA for fluorescence-guided surgery. Surg Oncol. 2017;26:153–162.
   PubMed Web of Science ®Google Scholar
• Sultana A, Shore S, Raraty MG, et al. Randomised phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I131KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma. BMC Cancer. 2009;9:66.
   PubMed Web of Science ®Google Scholar
• Hajjar G, Sharkey RM, Burton J, et al. Phase I radioimmunotherapy trial with iodine-131—labeled humanized MN-14 anti—carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. Clin Colorectal Cancer. 2002;2:31–42.
   PubMedGoogle Scholar
• Ballehaninna UK, Chamberlain RS. Serum CA 19-9 as a biomarker for pancreatic cancer—a comprehensive review. Indian J Surg Oncol. 2011;2:88–100.
   PubMedGoogle Scholar
• Loy TS, Sharp SC, Andershock CJ, et al. Distribution of CA 19-9 in adenocarcinomas and transitional cell carcinomas. An immunohistochemical study of 527 cases. Am J Clin Pathol. 1993;99:726–728.
   PubMed Web of Science ®Google Scholar
• McElroy M, Kaushal S, Luiken GA, et al. Imaging of primary and metastatic pancreatic cancer using a fluorophore-conjugated Anti-CA19-9 antibody for surgical navigation. World J Surg. 2008;32:1057–1066.
   PubMed Web of Science ®Google Scholar
• Hiroshima Y, Maawy A, Zhang Y, et al. Metastatic recurrence in a pancreatic cancer patient derived orthotopic xenograft (PDOX) nude mouse model is inhibited by neoadjuvant chemotherapy in combination with fluorescence-guided surgery with an anti-CA 19-9-conjugated fluorophore. PloS One. 2014;9:e114310.
   PubMed Web of Science ®Google Scholar
• Rosen AV, Linder S, Harmenberg U, et al. Serum levels of CA 19-9 and CA 50 in relation to lewis blood cell status in patients with malignant and benign pancreatic disease. Pancreas. 1993;8:160–165.
   PubMed Web of Science ®Google Scholar
• Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2007;33:266–270.
   Google Scholar
• Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med. 2014;20:332–342.
   PubMed Web of Science ®Google Scholar
• Qu CF, Li Y, Song YJ, et al. MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate. Br J Cancer. 2004;91:2086–2093.
   PubMed Web of Science ®Google Scholar
• Park JY, Hiroshima Y, Lee JY, et al. MUC1 selectively targets human pancreatic cancer in orthotopic nude mouse models. PloS One. 2015;10:e0122100.
   PubMed Web of Science ®Google Scholar
• Fan X-N, Karsten U, Goletz S, et al. Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas. Pathol Res Pract. 2010;206:585–589.
   PubMed Web of Science ®Google Scholar
• Helft PR, Schilsky RL, Hoke FJ, et al. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004;10:4363–4368.
   PubMed Web of Science ®Google Scholar
• Troiani T, Martinelli E, Capasso A, et al. Targeting EGFR in pancreatic cancer treatment. Curr Drug Targets. 2012;13:802–810.
   PubMed Web of Science ®Google Scholar
• Rosenthal EL, Kulbersh BD, Duncan RD, et al. In vivo detection of head and neck cancer orthotopic xenografts by immunofluorescence. Laryngoscope. 2006;116:1636–1641.
   PubMed Web of Science ®Google Scholar
• Korb ML, Hartman YE, Kovar J, et al. Use of monoclonal antibody-IRDye800CW bioconjugates in the resection of breast cancer. J Surg Res. 2014;188:119–128.
   PubMed Web of Science ®Google Scholar
• Day KE, Sweeny L, Kulbersh B, et al. Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma. Mol Imaging Biol MIB Off Publ Acad Mol Imaging. 2013;15:722–729.
   PubMed Web of Science ®Google Scholar
• Moore LS, Rosenthal EL, Chung TK, et al. Characterizing the utilities and limitations of repurposing an open-field optical imaging device for fluorescence-guided surgery in head and neck cancer patients. J Nucl Med. 2016. jnumed.115.171413. 2017 Feb 1;58(2):246-251
   Web of Science ®Google Scholar
• Rosenthal EL, Warram JM, de Boer E, et al. Safety and tumor specificity of cetuximab-IRDye800 for surgical navigation in head and neck cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21:3658–3666.
   PubMed Web of Science ®Google Scholar
• Tummers WS, Miller SE, Teraphongphom NT, et al. Intraoperative pancreatic cancer detection using tumor-specific multimodality molecular imaging. Ann Surg Oncol. 2018.
   PubMedGoogle Scholar
• Liang Q-L, Wang B-R, Chen G-Q, et al. Clinical significance of vascular endothelial growth factor and connexin43 for predicting pancreatic cancer clinicopathologic parameters. Med Oncol Northwood Lond Engl. 2010;27:1164–1170.
   PubMed Web of Science ®Google Scholar
• Itakura J, Ishiwata T, Friess H, et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res Off J Am Assoc Cancer Res. 1997;3:1309–1316.
   PubMed Web of Science ®Google Scholar
• Withrow KP, Newman JR, Skipper JB, et al. Assessment of bevacizumab conjugated to Cy5.5. for detection of head and neck cancer xenografts. Technol Cancer Res Treat. 2008;7:61–66.
   PubMed Web of Science ®Google Scholar
• Tjalma JJ, Garcia-Allende PB, Hartmans E, et al. Molecular fluorescence endoscopy targeting vascular endothelial growth factor a for improved colorectal polyp detection. J Nucl Med Off Publ Soc Nucl Med. 2016;57:480–485.
   PubMed Web of Science ®Google Scholar
• Chang SK, Rizvi I, Solban N, et al. In vivo optical molecular imaging of vascular endothelial growth factor for monitoring cancer treatment. Clin Cancer Res. 2008;14:4146–4153.
   PubMed Web of Science ®Google Scholar
• Harlaar NJ, Koller M, de Jongh SJ, et al. Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study. Lancet Gastroenterol Hepatol. 2016;1:283–290.
   PubMed Web of Science ®Google Scholar
• Oliveira S, van Dongen GAMS, Stigter-van Walsum M, et al. Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. Mol Imaging. 2012;11:33–46.
   PubMed Web of Science ®Google Scholar
• Devoogdt N, Xavier C, Hernot S, et al. Molecular imaging using nanobodies: a case study. Methods Mol Biol Clifton NJ. 2012;911:559–567.
   PubMedGoogle Scholar
• Debie P, Vanhoeij M, Poortmans N, et al. Improved debulking of peritoneal tumor implants by near-infrared fluorescent nanobody image guidance in an experimental mouse model. Mol Imaging Biol MIB Off Publ Acad Mol Imaging. 2018 June;20(3):361–367.
   Google Scholar
• Mahalingam SM, Dudkin VY, Goldberg S, et al. Evaluation of a centyrin-based near-infrared probe for fluorescence-guided surgery of epidermal growth factor receptor positive tumors. Bioconjug Chem. 2017;28:2865–2873.
   PubMed Web of Science ®Google Scholar
• Muyldermans S, Atarhouch T, Saldanha J, et al. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng. 1994;7:1129–1135.
   PubMedGoogle Scholar
• Goldberg SD, Cardoso RMF, Lin T, et al. Engineering a targeted delivery platform using centyrins. Protein Eng Des Sel PEDS. 2016;29:563–572.
   PubMed Web of Science ®Google Scholar
• Urano Y, Asanuma D, Hama Y, et al. Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med. 2009;15:104.
   PubMed Web of Science ®Google Scholar
• Obaid G, Spring BQ, Bano S, et al. Activatable clinical fluorophore-quencher antibody pairs as dual molecular probes for the enhanced specificity of image-guided surgery. J Biomed Opt. 2017;22:1–6.
   PubMed Web of Science ®Google Scholar
• Hong G, Antaris AL, Dai H. Near-infrared fluorophores for biomedical imaging. Nat Biomed Eng. 2017;1:s41551-016-0010–0016.
   Web of Science ®Google Scholar
• Adams KE, Ke S, Kwon S, et al. Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer. J Biomed Opt. 2007;12:024017.
   PubMed Web of Science ®Google Scholar
• Frangioni JV. In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol. 2003;7:626–634.
   PubMed Web of Science ®Google Scholar
• Tummers QRJG, Verbeek FPR, Schaafsma BE, et al. Real-time intraoperative detection of breast cancer using near-infrared fluorescence imaging and methylene blue. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2014;40:850–858.
   Google Scholar
• van der Vorst JR, Schaafsma BE, Verbeek FPR, et al. Intraoperative near-infrared fluorescence imaging of parathyroid adenomas with use of low-dose methylene blue. Head Neck. 2014;36:853–858.
   PubMed Web of Science ®Google Scholar
• Winer JH, Choi HS, Gibbs-Strauss SL, et al. Intraoperative localization of insulinoma and normal pancreas using invisible near-infrared fluorescent light. Ann Surg Oncol. 2010;17:1094–1100.
   PubMed Web of Science ®Google Scholar
• van der Vorst JR, Vahrmeijer AL, Hutteman M, et al. Near-infrared fluorescence imaging of a solitary fibrous tumor of the pancreas using methylene blue. World J Gastrointest Surg. 2012;4:180–184.
   PubMedGoogle Scholar
• Schaafsma BE, Mieog JSD, Hutteman M, et al. The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery. J Surg Oncol. 2011;104:323–332.
   PubMed Web of Science ®Google Scholar
• Kamisaka K, Listowsky I, Betheil JJ, et al. Competitive binding of bilirubin, sulfobromophthalein, indocyanine green and other organic anions to human and bovine serum albumin. Biochim Biophys Acta. 1974;365:169–180.
   PubMed Web of Science ®Google Scholar
• Karampinis I, Ronellenfitsch U, Mertens C, et al. Indocyanine green tissue angiography affects anastomotic leakage after esophagectomy. A retrospective, case-control study. Int J Surg Lond Engl. 2017;48:210–214.
   PubMed Web of Science ®Google Scholar
• Jafari MD, Wexner SD, Martz JE, et al. Perfusion assessment in laparoscopic left-sided/anterior resection (PILLAR II): a multi-institutional study. J Am Coll Surg. 2015;220:8292.e1.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Nishimori H, Handa T, et al. Quantitative assessment technique of HyperEye medical system angiography for coronary artery bypass grafting. Surg Today. 2017;47:210–217.
   PubMed Web of Science ®Google Scholar
• Settembre N, Kauhanen P, Albäck A, et al. Quality control of the foot revascularization using indocyanine green fluorescence imaging. World J Surg. 2017;41:1919–1926.
   PubMed Web of Science ®Google Scholar
• Naz I, Walters E, Akbari CM, et al. Noninvasive vascular assessment of lower extremity wounds in diabetics: are we able to predict perfusion deficits? Surg Technol Int. 2017 Oct 12;31:66-74.
   Google Scholar
• Ishizawa T, Bandai Y, Kokudo N. Fluorescent cholangiography using indocyanine green for laparoscopic cholecystectomy: an initial experience. Arch Surg Chic. Ill 1960. 2009;144:381–382.
   PubMedGoogle Scholar
• Ishizawa T, Fukushima N, Shibahara J, et al. Real-time identification of liver cancers by using indocyanine green fluorescent imaging. Cancer. 2009;115:2491–2504.
   PubMed Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release Off J Control Release Soc. 2000;65:271–284.
   PubMed Web of Science ®Google Scholar
• Hutteman M, van der Vorst JR, Mieog JSD, et al. Near-infrared fluorescence imaging in patients undergoing pancreaticoduodenectomy. Eur Surg Res Eur Chir Forsch Rech Chir Eur. 2011;47:90–97.
   PubMed Web of Science ®Google Scholar
• Newton AD, Predina J, Mizelle J, et al. Intraoperative near-infrared imaging with second window indocyanine green for pancreatic adenocarcinoma. J Am Coll Surg. 2017;225:S193.
   Web of Science ®Google Scholar
• Majlesara A, Golriz M, Hafezi M, et al. Indocyanine green fluorescence imaging in hepatobiliary surgery. Photodiagnosis Photodyn Ther. 2017;17:208–215.
   PubMed Web of Science ®Google Scholar
• Katada T, Hashidate H, Yokoyama N, et al. Initial features of hepatic metastases from pancreatic cancer: histological and radiolographical appraisal of hepatic micrometastases detected by real-time fluorescent imaging. Pancreas. 2017;46:1196–1201.
   PubMed Web of Science ®Google Scholar
• Yokoyama N, Otani T, Hashidate H, et al. Real-time detection of hepatic micrometastases from pancreatic cancer by intraoperative fluorescence imaging: preliminary results of a prospective study. Cancer. 2012;118:2813–2819.
   PubMed Web of Science ®Google Scholar
• Zhu B, Sevick-Muraca EM. A review of performance of near-infrared fluorescence imaging devices used in clinical studies. Br J Radiol. 2015;88:20140547.
   PubMed Web of Science ®Google Scholar
• DSouza AV, Lin H, Henderson ER, et al. Review of fluorescence guided surgery systems: identification of key performance capabilities beyond indocyanine green imaging. J Biomed Opt. 2016;21:080901.
   PubMed Web of Science ®Google Scholar
• Cao HST, Kaushal S, Metildi CA, et al. Tumor-specific fluorescent antibody imaging enables accurate staging laparoscopy in an orthotopic model of pancreatic cancer. Hepatogastroenterology. 2012;59:1994–1999.
   PubMedGoogle Scholar
• Boogerd L, Vuijk FA, Hoogstins C, et al. Correlation between preoperative serum carcinoembryonic antigen levels and expression on pancreatic and rectal cancer tissue. Biomark Cancer. 2017;9:1179299X17710016.
   PubMedGoogle Scholar
• Moore LS, Rosenthal EL, de Boer E, et al. Effects of an unlabeled loading dose on tumor-specific uptake of a fluorescently labeled antibody for optical surgical navigation. Mol Imaging Biol MIB Off Publ Acad Mol Imaging. 2017;19:610–616.
   PubMed Web of Science ®Google Scholar